Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

被引：4

作者：

Harrison, Claire ^{[1
]}

Nangalia, Jyoti ^{[2
,3
,4
]}

Boucher, Rebecca H. ^{[5
]}

Jackson, Aimee ^{[5
]}

Yap, Christina ^{[5
,6
]}

O'Sullivan, Jennifer ^{[7
,8
,9
]}

Fox, Sonia ^{[10
]}

Ailts, Isaak ^{[11
]}

Dueck, Amylou C. ^{[12
]}

Geyer, Holly L. ^{[11
]}

Mesa, Ruben ^{[13
]}

Dunn, William ^{[4
]}

Nadezhdin, Eugene ^{[3
]}

Curto-Garcia, Natalia ^{[7
]}

Green, Anna ^{[14
]}

Wilkins, Bridget ^{[7
]}

Coppell, Jason ^{[15
]}

Laurie, John ^{[16
]}

Garg, Mamta ^{[17
]}

Ewing, Joanne ^{[18
]}

Knapper, Steve ^{[19
]}

Crowe, Josephine ^{[20
]}

Koutsavlis, Ioannis ^{[21
]}

Godfrey, Anna L. ^{[22
]}

Arami, Siamak ^{[23
]}

Drummond, Mark W. ^{[24
]}

Byrne, Jennifer ^{[22
]}

Clark, Fiona J. ^{[25
,26
]}

Mead-Harvey, Carolyn ^{[12
]}

Baxter, Joanna E. ^{[27
]}

McMullin, Mary Frances ^{[28
]}

Mead, Adam J. ^{[8
,9
,29
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

[2] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[3] Wellcome Sanger Inst Hinxton, Hinxton, Cambs, England

[4] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[5] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England

[6] Inst Canc Res, Clin Trials & Stat Unit, London, England

[7] Guys & St Thomas NHS Fdn Trust, London, England

[8] Univ Oxford, Med Res Council Weatherall Inst Mol Med, Oxford, England

[9] Univ Oxford, NIHR Biomed Res Ctr, Oxford, England

[10] Univ Birmingham, Clin Trials Unit, Canc Res UK, Birmingham, W Midlands, England

[11] Mayo Clin, Dept Internal Med, Scottsdale, AZ USA

[12] Mayo Clin, Dept Quantitat Hlth Sci, Scottsdale, AZ USA

[13] UT Hlth San Antonio, Mays Canc Ctr, San Antonio, TX USA

[14] Guys & St ThomasNHS Fdn Trust, Dept Histopathol, London, England

[15] Royal Devon & Exeter Hosp, Exeter, Devon, England

[16] Worthing Dist Hosp, Worthing, England

[17] Univ Hosp Leicester, Leicester, Leics, England

[18] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[19] Cardiff Univ, Sch Med, Cardiff, Wales

[20] Royal United Hosp, Bath, Avon, England

[21] Western Gen Hosp, Lothian Hlth Board, Edinburgh, Midlothian, Scotland

[22] Cambridge Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Cambridge, England

[23] London North West Univ Healthcare NHS Trust, Harrow, Middx, England

[24] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[25] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England

[26] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Cambridge, England

[27] Cambridge Blood & Stem Cell Biobank NHS BT Cambri, Haematol, Cambridge, England

[28] Queens Univ, Ctr Med Educ, Belfast, Antrim, North Ireland

[29] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Canc & Haematol Ctr, Oxford, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157273

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1781 / 1783

页数：3

共 50 条

[41] Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Nikolas von Bubnoff
Gabriele Ihorst
Olga Grishina
Nadine Röthling
Hartmut Bertz
Justus Duyster
Jürgen Finke
Robert Zeiser
BMC Cancer, 18
[42] The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
Mesa, Ruben
Vannucchi, Alessandro M.
Yacoub, Abdulraheem
Zachee, Pierre
Garg, Mamta
Lyons, Roger
Koschmieder, Steffen
Rinaldi, Ciro
Byrne, Jennifer
Hasan, Yasmin
Passamonti, Francesco
Verstovsek, Srdan
Hunter, Deborah
Jones, Mark M.
Zhen, Huiling
Habr, Dany
Martino, Bruno
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (01) : 76 - 85
[43] RUXOLITINIB PROVES SUPERIOR TO BEST AVAILABLE THERAPY IN PATIENTS WITH POLYCYTHEMIA VERA (PV) AND A NONPALPABLE SPLEEN: RESULTS FROM THE PHASE IIIB RESPONSE-2 STUDY
Passamonti, F.
Griesshammer, M.
Palandri, F.
Egyed, M.
Benevolo, G.
Devo, T.
Callum, J.
Vannucchi, A. M.
Sivgin, S.
Bensasson, C.
Khan, M.
Mounedji, N.
Saydam, G.
HAEMATOLOGICA, 2016, 101 : 7 - 7
[44] Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results
Mesa, Ruben
Verstovsek, Srdan
Kiladjian, Jean-Jacques
Griesshammer, Martin
Masszi, Tamas
Durrant, Simon
Passamonti, Francesco
Harrison, Claire N.
Pane, Fabrizio
Zachee, Pierre
He, Shui
Jones, Mark M.
Parasuraman, Shreekant
Li, Jingjin
Cote, Isabelle
Habr, Dany
Vannucchi, Alessandro M.
BLOOD, 2014, 124 (21)
[45] Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Koschmieder, Steffen
Isfort, Susanne
Heidel, Florian H.
Hochhaus, Andreas
Becker, Heiko
Jost, Philipp J.
Schafhausen, Philippe
Griesshammer, Martin
Wolleschak, Denise
Haenel, Mathias
Goethert, Joachim R.
Teichmann, Lino L.
Sockel, Katja
Radsak, Markus P.
Reiter, Andreas
Doehner, Konstanze
Balleisen, Sebastian
Jaekel, Nadja
von Bubnoff, Nikolas
Stegelmann, Frank
Gezer, Deniz
Kortmann, Maike
Frank, Julia
Hellmich, Martin
Bruemmendorf, Tim H.
BLOOD, 2022, 140 : 1790 - 1793
[46] Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available
Devos, Timothy
Pica, Gian Matteo
Zerazhi, Hacene
Van Droogenbroeck, Jan
Visanica, Sorin
de la Fuente, Enrique Baez
Leber, Brian
de Almeida, Antonio Medina
Ranta, Dana
Martinez, Tomasa
Kiladjian, Jean-Jacques
Chrit, Linda
Yin, Zhaoyu
Foltz, Julian Perez Roncoand Lynda
BLOOD, 2017, 130
[47] COST-EFFECTIVENESS ANALYSIS OF RUXOLITINIB VS BEST AVAILABLE THERAPY FOR THE TREATMENT OF MYELOFIBROSIS IN THE UNITED STATES
Smith, A.
Martin, B. C.
VALUE IN HEALTH, 2022, 25 (07) : S394 - S395
[48] Ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease: a comparison of response by organ class from the randomized, phase 3 REACH2 study
Mohty, M.
Zeiser, R.
Galvin, J.
Wilke, C.
Tian, C.
Bhatt, V.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 39 - 40
[49] A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Dilley, Kimberley
Harb, Jason
Jalaluddin, Muhammad
Hutti, Jessica E.
Potluri, Jalaja
BLOOD, 2020, 136
[50] RANDOMIZED CONTROLLED TRIAL SHOWS QUALITY-OF-LIFE BENEFITS WITH VNS ADDED-ON TO BEST MEDICAL THERAPY VERSUS BEST MEDICAL THERAPY ALONE IN ADULTS WITH DRUG-RESISTANT EPILEPSY
Ryvlin, P.
Gilliam, F.
Nguyen, D.
Colicchio, G.
Pizzanelli, C.
Marrosu, F.
Tinuper, P.
Zamponi, N.
Aguglia, U.
Wagner, L.
Minotti, L.
Stefan, H.
Boon, P.
Sadler, M.
Benna, P.
Perucca, E.
EPILEPSIA, 2011, 52 : 83 - 83

← 1 2 3 4 5 →